ArticleCurrent issues in molecular biology2026
Rat TNF-Related Apoptosis-Inducing Ligand (rTRAIL)-Expressing Rat-Adipose-Derived Stem Cells (rADSC) Moderately Limit Growth of Rat Mammary Cancer Cells-A Pilot Study.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAdipose-derived stem cells (ADSCs) are readily harvestable, tumour-homing cells that have been engineered as vehicles for antitumour agents. TNF-related apoptosis-inducing ligand (TRAIL) selectively triggers apoptosis in many cancer cells through death receptors DR4/DR5, while sparing most healthy cells. To date, only human TRAIL has been studied in such delivery systems; a fully homologous rat model (rat TRAIL delivered by rat ADSC) has not been tested, despite being essential for future syngeneic in vivo studies.
methodsIn this pilot, exploratory study, we lentivirally transduced rat ADSC (rADSC) to express myc-tagged rat TRAIL, characterized the expression of TRAIL-pathway components in rADSC and three rat mammary carcinoma cell lines (RBA, HH-16.cl.4, SHZ-88) at the mRNA and protein levels, and assessed the antitumour effect of rTRAIL-rADSC using recombinant TRAIL dose-response, supernatant transfer, direct co-culture, and nine-day insert co-culture assays.
resultsrADSCs were successfully transduced and produced cell-associated rat TRAIL (66.2 pg per 50,000 cells versus 4.4-5.7 pg in controls;
conclusionsIn this pilot study, homologous rat TRAIL delivered by rADSC is feasible and increases cell death in TRAIL-susceptible rat mammary cancer cells, but the effect is moderate at most, contact-dependent, and in one of two susceptible lines not attributable to TRAIL itself. These findings define both the potential and the limitations of a fully translational rat model of TRAIL-based biologic brachytherapy and provide a foundation for future in vivo studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.